FLT3 and acute myeloid leukemia: Firstly, targeted gene sequencing successively identified FLT3‐ITD, CEBPA, and NPM1 mutations which helped improve prognostic classification, the response evaluation through quantification of molecular residual disease, and launched the research on targeted therapies leading to the registration of midostaurin as the first FLT3 inhibitor in AML [6, 7].